Plasma Concentration Studies
PT-141
Bremelanotide
Vyleesi
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
CAS: 189691-06-3
A 7-amino acid cyclic peptide analog of alpha-MSH that activates melanocortin receptors MC3R and MC4R, FDA-approved for hypoactive sexual desire disorder and studied for sexual function in clinical research. Premium Research Peptide.
99%+ Purity
Purity Tested
Research Use Only
Laboratory Use
Peptide Profile
Peptide Type
Certificate of Analysis
Third Party Tested by Freedom Diagnostics
Compound Information
Technical specifications
What Is PT-141?
Cyclic heptapeptide analog of alpha-MSH, active metabolite of Melanotan II
Stability Information
Handle with care to maintain potency
Lyophilized (powder)
2-8°C • protect from light
Reconstituted
2-8°C • use within 30 days
Auto-injector (Vyleesi)
Room temperature
Sources & References
Peer-reviewed research
Obstetrics & Gynecology
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
2019 • DOI: 10.1097/AOG.
PMID: 31599840
Kingsberg SA, Clayton AH, Portman D,...
- View Source
International Journal of Impotence Research
PT-141: a melanocortin agonist for the treatment of sexual dysfunction
2004 • PMID: 12851303
Diamond LE, Earle DC, Rosen RC, et al.
- View Source
Journal of Sexual Medicine
An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by...
2006 • DOI: 10.1111/j.1743-6...
PMID: 16839319
Diamond LE, Earle DC, Heiman JR, et al.
- View Source
Journal of Women's Health
Safety Profile of Bremelanotide Across the Clinical Development Program
2022
- View Source
FDA
Vyleesi (bremelanotide) Prescribing Information
2019
- View Source
Medicina (Kaunas)
Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorder
2022 • PMID: 35056399
- View Source
PubChem Database
Bremelanotide - Compound Summary (CID 9941379)
- View Source
